S01E39 | The FAST Trial - Rapid AST for Gram-Negative Bacteremia

In this episode of PRISM Rounds, we review the JAMA FAST randomized clinical trial of rapid antimicrobial susceptibility testing for gram-negative bloodstream infections and the accompanying editorial, “Is FASTer Better?” The trial did not improve the primary DOOR outcome at 30 days, but rapid AST shortened antibiotic modification times and may be most useful when resistant organisms, septic shock, or ineffective empiric therapy are in play. We discuss why faster lab data alone may not improve mortality unless stewardship, drug availability, and bedside action close the loop.Educational only. Not medical advice. https://pubmed.ncbi.nlm.nih.gov/41999287/ Tags:Critical Care, ICU, Sepsis, Gram Negative Bacteremia, Antimicrobial Stewardship, Antibiotic Resistance, Rapid Diagnostics, AST, Bloodstream Infection, Infectious Diseases, JAMA, FAST Trial, FOAMed, FOMEd, Free Open Access Medical Education, Research Summary, Pulmonary Critical Care, Hospital Medicine, Pharmacy, Microbiology